10-Q: Spectral AI Reports Q2 2025 Results, Advances FDA Filing

Spectral AI, Inc. reported a reduced net loss for the second quarter of 2025, driven by decreased operating expenses, while advancing its DeepView System with an FDA De Novo application and securing new financing.

Summary

• Net loss for the six months ended June 30, 2025, improved to $(5.071) million from $(6.069) million in the comparable 2024 period.
• Operating loss for the six months ended June 30, 2025, improved to $(3.019) million from $(4.585) million in the comparable 2024 period.
• Research and development revenue decreased by 14.7% to $11.772 million for the six months ended June 30, 2025, compared to $13.804 million in the prior year, primarily due to less activity under the PBS BARDA Contract.
• Gross margin increased to 46.4% for the six months ended June 30, 2025, up from 45.3% in the comparable 2024 period, attributed to a higher concentration of direct labor as a component of overall revenue.
• Cash balance increased to $10.524 million as of June 30, 2025, from $5.157 million at December 31, 2024.
• The company completed its FDA De Novo application for the DeepView System in June 2025, seeking Class II medical device designation.
• Secured new Avenue Financing of up to $15.0 million, with an initial draw-down of $8.5 million, and raised an additional $2.7 million through an equity offering in March 2025.
• A material weakness in financial statement close process controls remains unremediated as of June 30, 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While revenue decreased, the company significantly improved its net and operating losses, bolstered its cash position through new financing, and achieved a critical milestone with the FDA De Novo application. The persistent material weakness in internal controls and the increase in accumulated deficit are notable concerns, but the strategic progress towards commercialization and strengthened liquidity provide a positive outlook.

Positives

• Net loss significantly improved to $(5.071) million for the six months ended June 30, 2025, compared to $(6.069) million in the prior year.
• Operating loss improved to $(3.019) million for the six months ended June 30, 2025, from $(4.585) million in the prior year.
• Gross margin increased to 46.4% for the six months ended June 30, 2025, indicating improved efficiency.
• Cash balance more than doubled to $10.524 million as of June 30, 2025, from $5.157 million at December 31, 2024, enhancing liquidity.
• Successfully filed the De Novo application for the DeepView System with the FDA in June 2025, a critical step towards commercialization in the U.S.
• Secured new long-term debt financing of $8.5 million from Avenue Capital Group and raised $2.7 million in equity, strengthening the capital structure.
• The DeepView System received UKCA marking in February 2024, paving the way for anticipated initial sales in the UK in 2026.
• Completed enrollment of the pivotal clinical study with 267 patients by the end of 2024, supporting regulatory submissions.

Negatives

• Research and development revenue decreased by 14.7% to $11.772 million for the six months ended June 30, 2025, compared to the prior year, reflecting reduced activity under the PBS BARDA Contract.
• Accumulated deficit increased to $(53.300) million as of June 30, 2025, from $(48.229) million at December 31, 2024.
• Warrant liabilities significantly increased to $10.555 million as of June 30, 2025, from $6.451 million at December 31, 2024, primarily due to changes in fair value and new warrant issuances, leading to non-cash losses.
• A material weakness in financial statement close process controls persists and has not yet been remediated as of June 30, 2025, impacting the effectiveness of disclosure controls and procedures.
• The company remains highly dependent on U.S. governmental contracts for revenue, with one customer (a U.S. government agency) accounting for 94% of total net receivables and 94% of research and development revenue for the six months ended June 30, 2025.

Risks

• Failure of preclinical studies and clinical trials for product development.
• Dependence on key personnel for operational success.
• Challenges in protecting proprietary technology from infringement.
• Reliance on third-party organizations for various aspects of the business.
• Risks associated with obtaining regulatory approval for products.
• Development of technological innovations by competitors.
• Compliance with evolving government regulations.
• Need to obtain additional financing to fund ongoing operations and future growth.
• Potential component shortages, longer lead times, and increased costs in the supply chain.
• Inability to mitigate the impact of delays and/or price increases in raw materials, electronic components, and freight.

Future Outlook

The company anticipates initial sales of the DeepView System in the UK to begin in 2026, following receipt of UKCA authorization. Future revenue streams are expected from a SaaS model for software licensing and the imaging device component. A second financing tranche of $6.5 million from Avenue Capital Group is contingent upon FDA clearance of the DeepView System and the completion of an additional $7.0 million equity raise. The company plans to partner with U.S. governmental agencies for expanded deployment of DeepView Systems to support mass casualty countermeasure directives and conduct health economic and outcome research to drive broader clinical adoption.

Management Comments

• Management believes the company has sufficient working capital to fund operations for at least one year beyond the release date of the condensed consolidated financial statements, supported by the PBS BARDA Contract and Avenue Financing.
• Management acknowledges that a material weakness in financial statement close process controls has not yet been remediated, but believes the condensed consolidated financial statements fairly present the financial condition, results of operations, and cash flows in all material respects.

Industry Context

Spectral AI operates in the rapidly evolving medical technology industry, leveraging Artificial Intelligence for predictive diagnostics. Its DeepView System targets burn wound assessment, a niche with significant clinical need for accurate and timely diagnosis. The company benefits from substantial U.S. government support through agencies like BARDA, MTEC, and DHA, which is crucial for funding research, development, and initial deployment. The focus on a SaaS model and proprietary imaging device aligns with broader trends in digital health and AI-driven medical devices, aiming to integrate advanced technology into clinical workflows for improved patient outcomes and resource optimization.

Corporate Governance

Related Party Transactions

• On March 19, 2024, Spectral IP received a $1.0 million investment from an affiliate of the company's largest stockholder, structured as a note payable.
• The Spectral IP Note was fully converted into 540,996 shares of Common Stock throughout the fourth quarter of 2024, representing a 5.00% discount to the closing price.
• On May 5, 2025, the company entered into an intellectual property license agreement with Spectral IP, granting a worldwide, non-exclusive license to one international patent asset for commercialization outside the company's core focus areas on market terms to be finalized.
• On November 4, 2024, Spectral IP entered into a purchase agreement to acquire all outstanding common stock of Sauvegarder Investment Management, Inc. in exchange for issuing Spectral IP common and preferred stock, and the company agreed to forfeit most of its Spectral IP shares.

Stakeholder Impact

• Shareholders: Impacted by the repricing of Public Warrants to $2.75 and potential future dilution from the contingent $7.0 million equity raise.
• Investors: Provided new capital through the Avenue Financing and equity raise, with warrants issued as part of the financing.
• Government Agencies (BARDA, MTEC, DHA): Remain key customers and funding sources, influencing the company's revenue and development trajectory.
• Customers (Healthcare Providers): Will benefit from the DeepView System's potential to provide more accurate and timely burn wound assessments upon commercialization.
• Employees: Stock-based compensation plans are in place, and staffing levels were adjusted due to changes in project focus.

Next Steps

• Await FDA clearance of the DeepView System for Class II medical device designation.
• Complete an additional $7.0 million equity raise to unlock the second tranche of Avenue Financing.
• Initiate commercial sales of the DeepView System in the UK in 2026.
• Expand deployment of DeepView Systems in the U.S. through governmental contracts for mass casualty countermeasure directives.
• Conduct health economic and outcome research to support broader clinical adoption of the DeepView System.
• Continue remediation efforts to address the material weakness in financial statement close process controls.

Key Dates

Recommendation

Spectral AI's Q2 2025 filing presents a mixed but strategically advancing picture. While revenue declined due to project completion, the company significantly improved its net and operating losses, demonstrating better cost management. The successful FDA De Novo application and securing new financing are crucial milestones that de-risk future commercialization and provide necessary liquidity. However, the persistent material weakness in internal controls and the increase in warrant liabilities (though largely non-cash) introduce elements of uncertainty. A seasoned investor would likely 'hold' to observe the outcome of the FDA clearance, the execution of the contingent equity raise, and the commencement of commercial sales in the UK. These upcoming events are critical catalysts that will provide clearer direction on the company's long-term growth trajectory and profitability, outweighing the current financial headwinds and governance concerns.

Keywords

Spectral AI, DeepView System, FDA De Novo, medical diagnostics, AI, burn wound assessment, quarterly report, financial results, BARDA, UKCA, medical technology, predictive analytics, liquidity, warrant liabilities